e-learning
resources
Berlin 2001
Monday 24.09.2001
Leukotriene receptor antagonists in clinical practice
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Activity of montelukast and metabolites against leukotrienes in human bronchus
H. Mechiche, E. Naline, C. Advenier, P. Birembaut, P. Devillier (Reims, Paris, France)
Source:
Annual Congress 2001 - Leukotriene receptor antagonists in clinical practice
Session:
Leukotriene receptor antagonists in clinical practice
Session type:
Thematic Poster Session
Number:
1772
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
H. Mechiche, E. Naline, C. Advenier, P. Birembaut, P. Devillier (Reims, Paris, France). Activity of montelukast and metabolites against leukotrienes in human bronchus. Eur Respir J 2001; 16: Suppl. 31, 1772
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: Diagnostic tools for Obstructive Sleep Apnoea in adults and children
Expert interview: Physiological classification of lung function impairment
Occupational exposures to respiratory diseases: A case-based discussion
Related content which might interest you:
Cysteinyl leukotrienes and leukotriene B
4
in expired breath condensate in patients with chronic asthma treated with montelukast
Source: Eur Respir J 2003; 22: Suppl. 45, 101s
Year: 2003
Measurements of prostaglandins E2 and D2 and their metabolites in exhaled breath condensate following bronchial provocation with aspirin in asthmatics
Source: Annual Congress 2013 –Genetics and mechanisms of, and tests for, allergy
Year: 2013
Role of leukotrienes in airway inflammation
Source: Annual Congress 2004 - Early management of inflammatory airway diseases - Can we do better?
Year: 2004
Imbalance of anti-inflammatory (lipoxin A4) and pro-inflammatory (leukotrien B4) arachidonic acid products in exhaled breath condensate of severe refractory asthma.
Source: International Congress 2014 – Airway biomarkers
Year: 2014
Effect of resolvin D1 on leukotriene D
4
-induced constriction of rat and human bronchioles
Source: Annual Congress 2013 –Asthma drugs: new findings
Year: 2013
Anti-inflammatory effects of roflumilast N-oxide and dexamethasone in human bronchial epithelial cells stimulated with toll-like receptor agonists
Source: Annual Congress 2013 –The pulmonary epithelium: recent developments
Year: 2013
Therapeutical impact of montelukast on exhaled leukotrienes in asthmatic children
Source: Eur Respir J 2006; 28: Suppl. 50, 210s
Year: 2006
Elevated IL-10 level but not cysteinyl leukotrienes (CysLT) release from leukocytes in vitro correlates with good response to treatment with montelukast in asthmatic patients
Source: International Congress 2014 – Asthma and COPD management
Year: 2014
Inhibitory effects of montelukast on mediator release by nasal epithelial cells from asthmatic subjects
Source: Annual Congress 2013 –The pulmonary epithelium: recent developments
Year: 2013
Upregulation of cysteinyl leukotriene receptors CysLT
1
and CysLT
2
by TGF-β
1
and LTE
4
on human bronchial epithelial cells
Source: Annual Congress 2006 - Airway epithelial cells in inflammation
Year: 2006
Bronchial responsiveness to leukotriene D
4
is resistant to inhaled fluticasone proprionate
Source: Eur Respir J 2005; 26: Suppl. 49, 575s
Year: 2005
Down-regulation of SLPI by cysteinyl leukotrienes in human bronchial epithelial cells can be reverted by glucocorticoids
Source: Annual Congress 2011 - Lung cell injury and repair
Year: 2011
Effects of salbutamol enantiomers on equine isolated bronchial airways
Source: Annual Congress 2009 - Models of chronic airways disease and therapy
Year: 2009
Anti-inflammatory effects of formoterol and fluticasone propionate in bronchial epithelial cells
Source: International Congress 2015 – Therapeutic approaches in inflammatory lung disease
Year: 2015
Protective effect of cysteinyl leukotriene receptor antagonist montelukast in bleomycin induced pulmonary fibrosis
Source: Eur Respir J 2007; 30: Suppl. 51, 111s
Year: 2007
Increased exhaled cysteinyl-leukotrienes, leukotriene B
4
and 8-isoprostane in exacerbation of COPD
Source: Eur Respir J 2001; 18: Suppl. 33, 248s
Year: 2001
The CysLT1 receptor antagonist montelukast blocks bronchoconstriction induced by inhaled leukotriene E4 in subjects with asthma
Source: International Congress 2015 – The immunology of allergic airway disease
Year: 2015
Assessment of sputum prostaglandins and leukotrienes in COPD exacerbations
Source: Annual Congress 2013 –Systemic and airway biomarkers in respiratory diseases
Year: 2013
Increased urinary leukotriene E4 concentration in patients with eosinophilic pneumonia
Source: Eur Respir J 2008; 32: 437-442
Year: 2008
Measurement of leukotrienes urinary excretion in patients with bronchial asthma
Source: Eur Respir J 2003; 22: Suppl. 45, 371s
Year: 2003
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept